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Natural products as lead structures:
chemical transformations to create
lead-like libraries
Mauro Pascolutti and Ronald J. Quinn*, r.quinn@griffith.edu.au
In this review, we analyze and illustrate the variation of the two main lead-like descriptors [molecular
weight (MW) and the partition coefficient (logP)] in the generation of libraries in which a natural
product (NP) is used as the guiding structure. Despite the different approaches used to create NP-like
libraries, controlling these descriptors during the synthetic process is important to generate lead-like
libraries. From this analysis, we present a schematic approach to the generation of lead-like libraries that
can be applied to any starting NP.
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aSince ancient times, NPs have been a significant
source for the treatment of diseases and ill-
nesses. Analysis of NPs over the past 30 years
revealed that approximately 40% of the devel-
oped therapeutics drugs approved by the US
Food and Drug Administration (FDA) were NPs,
NP derivatives, or synthetic mimetics related to
NPs [1]. Investigation of structural differences
between NPs, drug substances and other che-
micals, found that NPs interrogate a different
and wider chemical space compared with syn-
thetic derivatives [2–5]. Furthermore, it has been
showed that 83% of core ring scaffolds present
in NPs were absent from commercially available
molecules and screening libraries [6]. It was
concluded that including molecules with a1359-6446/06  2013 The Authors. Published by Elsevier Ltd. Open acceNP-like scaffold into the screening library would
increase hit rates [6].
With their highly and sophisticated biological
and chemical diversity, NPs and their derivatives
have been used to explore biologically relevant
space [7,8]. The significant impact of NPs on the
discovery of therapeutic agents is based on their
embedded biosynthetic molecular recognition
[9]. Despite the pivotal role of NPs in drug
discovery [10–12], their use over the past two
decades has decreased in the pharmaceutical
industry [1]. This unfortunate downturn is mainly
attributed to the availability of the materials, and
the time and cost of isolating and identifying
active NPs from extracts [10,11,13]. However,
these limitations inspired the design of NP-like
libraries based on small molecules with
improved stability and bioavailability.
To capture NP-like characteristics, the gen-
eration of a library can be planned following four
main approaches: (i) target-oriented synthesis
(TOS) [14,15]; (ii) diversity-oriented synthesis
(DOS) [14,16]; (iii) biology-oriented synthesishttp://dx.doi.org/10.1016ss under CC BY-NC-ND license.(BIOS) [17,18]; and (iv) functional-oriented
synthesis (FOS) [19]. Although in-depth discussion
of these strategies is beyond the scope of this
review, two points are worth noting: (i) a library
collection that is diverse in chemical space is
generally used to explore a wide spectrum of
biological targets; and vice versa (ii) a less che-
mically diverse or focused library is mostly used to
explore a smaller biological target area.
Analysis of libraries using concepts of
lead-likeness
In 1997, Lipinsky proposed a set of four simple
physicochemical properties (rule of five, Ro5)
that were common to 90% of more than 2000
drugs and candidate drugs at or beyond phase II
clinical trials [20]. In essence, to be drug-like, a
candidate molecule should have less than five
hydrogen bond donors (HBD  5), less than ten
hydrogen bond acceptors (HBA  10), a
MW  500 Da and a logP  5 [20]. All these
parameters help to identify potential bioavail-
ability issues if two or more violations occur [20]./j.drudis.2013.10.013 www.drugdiscoverytoday.com 215
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TABLE 1
Selected examples of natural product-like libraries
Leading NP NP-like library Leading NP NP-like library
Library 1 [37] Library 2a [38]
Library 3 [39] Library 4 [40]
Library 5 [41] Library 6 [42]
Library 7 [43] Library 8 [44]
Library 9 [45] Library 10 [46]
Library 11b [47] Library 12 [48]
Library 13b [49] Library 14 [50]
Library 15 [51] Library 16 [52]
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TABLE 1 (Continued )
Leading NP NP-like library Leading NP NP-like library
Library 17c [53] Library 18 [54]
Library 19 [55] Library 20 [56]
Library 21 [57] Library 22 [58]
Library 23 [59] Library 24b [60]
a A privileged scaffold is represented instead of the leading NP.
b Listed are the most representative NPs used in the library design.
c Although the library was generated focusing on the macroline family, the guiding natural product is reported here.
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measure of drug-likeness based on the concept
of desirability called the ‘quantitative estimate of
drug-likeness’ (QED) [21]. This new concept was
introduced because they observed that Lipins-
ky’s rule could sometimes be misleading [21]. For
example, undesirable compounds can satisfy the
Ro5 and, therefore, pass the drug-likeness cri-
teria, whereas more appropriate compounds can
fail because of the violation of one or more cut-
offs. QED is an integrated function of eight
desirability functions calculated for each physi-
cochemical properties: MW, logP, HBD, HBA, polar
surface area, rotatable bonds (RTB), aromatic ring
count (RNG) and number of alerts. Moreover, each
molecular descriptor is weighted by its relative
significance in the contribution to drug-likeness.
As Leeson pointed out [22], QED is not the final
word in understanding the features of drug-like-
ness, but provides a richer and more balanced
view on this concept compared to Ro5. Therefore,
this new parameter could be used in the lead
optimization process or potentially for the gen-
eration of libraries with lead-like properties.
Contrary to drug-like properties, which are still
mostly represented by Ro5, lead-like properties
are more restricted. This is because the identi-
fication of lead compounds is the starting point
for further development in drug design [23]. Alead is a less complex compound with defined
physicochemical properties, suitable for further
manipulation and optimization to generate a
drug-like compound. Lead-likeness was first
introduced by Opera in 1999, who suggested
that lead-like compounds should have the fol-
lowing requirements: MW  350 Da and
logP  3 [24]. This concept was then further
elaborated by taking into consideration other
physical properties, such as HBA, HBD, RTB, RNG
and its aqueous solubility (LogS). More impor-
tantly, the range of MW was extended to 460 Da
and the logP values to between 4 and 4.2
[25,26]. Meanwhile, an analysis by Leeson and
Davis [27] of 864 drugs approved before 1983
compared with 329 drugs approved between
1983 and 2002 showed that the logP values
remained consistent over time, with minor
changes compared with the other physico-
chemical properties. Since the first guidelines of
lead-likeness were established, several publica-
tions over the past decade have reported var-
iations of this concept, either introducing new
physicochemical properties or slightly modifying
the existing range values [28–33].
In this review, we analyze and illustrate the
variation of the two main lead-like descriptors (MW
and logP) in the generation of NP-like libraries in
which a NP is used as the guiding structure. Foreach library, an analysis of four physicochemical
properties (HBD, HBA, RTB and RNG) is presented.
To provide a more comprehensive analysis, 24
libraries (Table 1) were selected based on dif-
ferent features. (i) Origin of the library. Two
major categories of library were selected: NP-
derived and NP-inspired libraries. Molecules in
which the scaffold is identical to the scaffold of a
leading NP belong to the first category, whereas
compounds in which the scaffold is closely
related to the guiding NP fall into the second
category. In this collection, most libraries are
based on one NP representative. However, in a
few examples, more than one NP was taken as
the guiding structure. Library 8 was created
considering four NPs that were based on the
same quinone moiety. Library 19 was based on
two sesquiterpenes, artemisinin and anthecu-
larin, bearing a peroxide bridge and a diene,
respectively. In our selection, we also included
NP-like libraries based on a common structural
motif. In this category, we included library 2,
which was generated around the privileged
scaffold 2,2-dimethyl-2H-benzopyran, and
libraries 11, 13 and 24 based on spiroketal,
diaza-bridge and macrolactone scaffolds,
respectively; (ii) MW: a wide range in MW of the
representative NPs was chosen (from 130 Da to
940 Da); (iii) Library size; small libraries of 10–15www.drugdiscoverytoday.com 217
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FIGURE 1
Analysis of 24 natural product (NP)-like libraries based on two physicochemical properties: molecular weight (MW) in Dalton (x) and the partition coefficient (logP)
(y). In each chart, values are plotted of the guiding NP(s) in red and the library of the compound in black. aLibraries with >100 compounds were filtered to generate
smaller libraries with similar chemical diversity.
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FIGURE 2
Summary of calculated physicochemical properties for 24 libraries: (a) hydrogen bond donors (HBD); (b) hydrogen bond acceptors (HBA); (c) rotatable bonds (RTB);
and (d) ring count (RNG).
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analyzed.
The initial analysis of the 24 libraries was
carried out by generating scatterplots using MW
and logP as the two variables. From the data sets
summarized in Fig. 1, three major distribution
trends were identified, as discussed below.
Rising libraries
Rising libraries contained compound collections
with higher MWs than the guiding NP. In most
cases, logP values rose in direct proportion to
MW (libraries 1, 3, 7, 10, 12 and 17). In two cases
(libraries 1 and 10), the distribution values were
not as compact as in the other examples and
different linearity sets can be observed within
the same library. However, an increase of MW did
not always lead to a rise in logP, as shown for
libraries 15, 16 and 22. In these three plots, the
logP vales of the libraries are both below and
above the guiding NP.
Falling libraries
This second trend of distribution is characterized
by libraries with a MW lower than the guiding NP.
By decreasing the MW, two different sets were
identified: libraries with LogP values lower than
the guiding NP, in which the logP decreaseddirectly proportional to the MW (libraries 4 and
8); and libraries with logP values predominantly
above the guiding NP (libraries 6, 9, 14 and 18). In
this trend, we also included libraries 11, 13 and
24. As expected, because these three libraries
were generated using the common structural
motif approach, a decrease in MW compared
with the guiding NPs was detected. In the first
two examples, a linear decrease of logP values
was observed, whereas library 24 showed a more
scattered distribution of values.
Uncorrelated libraries
This class was characterized by libraries having
both lower and higher MW compounds com-
pared with the guiding NP. In two examples
(libraries 5 and 23), most compounds in the
library had logP values above the guiding NP.
However, the opposite distribution, in which a
predominant part of the library entities have
logP values below the guiding NP (libraries 19,
20 and 21), was also observed. Given that
library 2 was generated using a privileged
scaffold approach, only selected examples of
benzopyran-containing NP were plotted. In
this case, we observed a library built with
similar physicochemical properties as the
guiding NPs.As mentioned above, a more complete ana-
lysis of lead-likeness should include additional
physicochemical properties, such as HBD, HBA,
RNG and RTB. The analysis of individual prop-
erties is summarized in Fig. 2 expressed as
percentages. The histogram of the HBDs (Fig. 2a)
shows a predominant distribution that peaks at
1–3, and values >5 are rarely reached. In a few
examples (libraries 4, 6, 9 and 14), there was a
lack of HBD distribution, showing predominately
just one value of HBD within the library. The
histogram in Fig. 2b, which indicates HBA dis-
tribution, shows values for most of the libraries,
with a maximum at 4–7 HBA. Despite the first
two distributions, in which we were able to
define a range of maximum values for HBD and
HBA, the histogram representing the number of
RTB (Fig. 2c) showed more scattered values.
However, approximately 75% of the libraries fell
into the lead-likeness cut-off value (RTB  9).
Furthermore, RNG was calculated and the
values for each library are summarized in
Fig. 2d. For this property, a major distribution
is observed, with peak values of between 3 and
5 RNG.
Although the 24 selected libraries were cre-
ated using different synthetic strategies and not
necessary with the ultimate goal to generate awww.drugdiscoverytoday.com 219
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FIGURE 3
Schematic approaches (a and b) to the generation of lead-like libraries. Representation of the lead-like region (green) of four libraries selected from Fig. 1 (c).
Abbreviations: logP: partition coefficient; MW: molecular weight.
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analysis the impact of chemical transformations
on physiochemical properties in the generation
of libraries using NPs as a guiding structure.
Chemical transformations to create lead-
like libraries
From this analysis, we present a schematic
approach to the generation of lead-like libraries
that can be applied to any starting NP. Given that,
during the lead-optimization process, an
increase in MW and logP is generally observed
[24,34], we believe that the optimum property
cut-off values to identify NP lead-like libraries
should be as follows: MW  350 Da and
1  logP  3. The initial step to generate
potential leads is to define the guiding NP with
relevant biological activity. Next, the NP-like
library can be created following three different
approaches, as simplified in Fig. 3: (i) if the
guiding NP has a MW  350 Da, it is necessary to
reduce the structural complexity. This can be
achieved through the identification of scaffolds.
The synthetic process to produce attractive
scaffolds should take in consideration the
insertion of several functional groups, which
could then be elaborated [35,36]. This is a crucial
point in the generation of potential leads
because functionalization of these molecules
should provide a library with appropriate logP220 www.drugdiscoverytoday.comvalues (1  logP  3) and, at the same time,
with chemical diversity. As we observed in our
previous analysis in Fig. 1, a reduction in struc-
tural complexity can lead to a library with
optimal logP values, as in library 4, and to a
library with logP values in the non-lead-like
region, as in library 6 (Fig. 3). Therefore, the
challenge will be to create small molecule
libraries within the lead-like region starting from
NP scaffolds in which the main features of the
guiding NP are retained; (ii) if the guiding NP has
a MW  350 and logP  3, is it necessary to
reduce lipophilicity. Library 21 (Fig. 3) is a typical
example of this situation. Moreover, to provide
chemical diversity within the library, the pre-
sence of several functional groups is necessary;
and (iii) if the guiding NP falls in the lead-like
region, as in library 20 (Fig. 3), this can be used as
a starting point for the preparation of a library
with skeletal and stereochemical variations with
the condition to generate molecules in the lead-
like region.
Concluding remarks
In conclusion, despite the different approaches
used to create NP-like libraries, we believe that
controlling the two main descriptors (MW and
logP) during the synthetic process would facil-
itate the generation of lead-like libraries.
Therefore, the use of in silico analysis in scaffoldidentification and elaboration will avoid the
generation of unwanted entities with resulting
improvement in the quality of the library.
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